KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Common Equity (2016 - 2025)

Alnylam Pharmaceuticals' Common Equity history spans 17 years, with the latest figure at $789.2 million for Q4 2025.

  • For Q4 2025, Common Equity rose 1076.33% year-over-year to $789.2 million; the TTM value through Dec 2025 reached $789.2 million, up 1076.33%, while the annual FY2025 figure was $789.2 million, 1076.33% up from the prior year.
  • Common Equity reached $789.2 million in Q4 2025 per ALNY's latest filing, up from $233.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $926.2 million in Q1 2021 to a low of -$408.1 million in Q2 2023.
  • Average Common Equity over 5 years is $184.4 million, with a median of $91.3 million recorded in 2024.
  • Peak YoY movement for Common Equity: plummeted 331.84% in 2023, then soared 8270.56% in 2025.
  • A 5-year view of Common Equity shows it stood at $588.2 million in 2021, then tumbled by 126.9% to -$158.2 million in 2022, then tumbled by 39.45% to -$220.6 million in 2023, then skyrocketed by 130.41% to $67.1 million in 2024, then soared by 1076.33% to $789.2 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Common Equity are $789.2 million (Q4 2025), $233.9 million (Q3 2025), and $250.6 million (Q2 2025).